New and emerging agents in HER2-negative metastatic breast cancer Implications for current and future practice

touchPANEL DISCUSSION for touchONCOLOGY Listen to three breast cancer experts discuss the expanding targeted treatment options for HER2-negative metastatic breast cancer, with a focus on approved and emerging antibody drug conjugates and considerations for their use in clinical practice.  The experts Prof. Giuseppe Curigliano, University of Milan, Milan, Italy Prof. Hope Rugo, University of California, San Francisco, CA, USA Prof. Peter Schmid, Barts Cancer Institute, London, UK This touchPODCAST is for HCPs only. This activity is funded by an independent medical education grant from Gilead Sciences, Inc. This activity is jointly provided by USF Health and touchIME. For further information visit our website: https://touchoncologyime.org/new-and-emerging-agents-in-her2negative-mbc